NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it for free.

Test my supply
+3 more ↓
76%
Finnrick rating
#147 of 200 Tirzepatide vendors
45 of 61 classifiable tests passed
customers 4.4★ (37)
methodology · Purity focus
Finnrick analysis · Tirzepatide

Nexaph's tirzepatide profile is pulled down by early purity misses and severe fill outliers, including +59%, +43%, and +78% overfills. The recent run is steadier, but batch-ID gaps mean the streak should be read with lot documentation.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Corporate records, RDAP data and site emails trace Nexaph through a fragmented operator identity rather than a clean public counterparty. The report maps sister-brand infrastructure, COA-cloning pathways and a certification/payment layer that changes buyer recourse.

31 pages8 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
90%
11
2
Tirzepatideselected
$1.08
76%
61
3
Retatrutide
$2.46
73%
101
4
Ipamorelin
$1.30
60%
10
5
BPC-157
$1.28
57%
17
6
Cagrilintide
$3.50
55%
12
7
TB-500
$1.61
37%
6
8
Tesamorelin
$2.88
34%
29
9
Semaglutide
$1.90
33%
15
10
CJC-1295
$2.78
30%
8
11
MOTS-c
$1.88
24%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%2 Jul 2025: 61%2 Jul 2025: 58%3 Jul 2025: 54%16 Jul 2025: 56%17 Jul 2025: 59%3 Aug 2025: 57%3 Aug 2025: 54%3 Aug 2025: 51%5 Aug 2025: 53%5 Aug 2025: 50%5 Aug 2025: 52%5 Aug 2025: 49%6 Aug 2025: 51%7 Aug 2025: 48%11 Aug 2025: 51%31 Aug 2025: 53%1 Sept 2025: 51%4 Sept 2025: 53%18 Sept 2025: 55%6 Oct 2025: 58%17 Oct 2025: 59%17 Oct 2025: 61%17 Oct 2025: 62%24 Oct 2025: 63%30 Oct 2025: 61%18 Nov 2025: 62%13 Dec 2025: 64%18 Dec 2025: 65%29 Dec 2025: 66%15 Jan 2026: 67%19 Jan 2026: 65%19 Jan 2026: 66%11 Feb 2026: 67%11 Feb 2026: 68%11 Feb 2026: 69%11 Feb 2026: 70%13 Feb 2026: 70%18 Feb 2026: 68%20 Feb 2026: 69%25 Feb 2026: 70%2 Mar 2026: 71%3 Mar 2026: 71%4 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 71%6 Mar 2026: 72%25 Mar 2026: 72%28 Apr 2026: 73%6 May 2026: 74%11 May 2026: 74%12 Jun 2026: 75%15 Jun 2026: 75%15 Jun 2026: 76%26 Jun 2026: 76%21 Jul 2026: 77%4 Aug 2026: 77%26 Aug 2026: 78%27 Aug 2026: 76%3 Sept 2026: 75%10 Sept 2026: 75%10 Sept 2026: 76%15 Sept 2026: current 76%61%64%76%Jul 25Sep 26
Showing Tirzepatide tests only
Free peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it for free.

Test my supply
Nexaph Tirzepatide test history
COA-backed lab tests
1-10 of 61

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 275 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it for free.

Test my supply